drugset / Trial / NCT00174889

Pregnenolone in the Management of Schizophrenia Patients

NCT00174889

RandomizedParallel-groupDouble-blindTreatment

Summary

Pregnenolone is a "neurosteroid" and possesses intrinsic behavioral and brain effects in animals, affecting the GABA(A) and other receptors. Pregnenolone is serves as the precursor for dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS). There is evidence of efficacy of DHEA augmentation in schizophrenia, we therefore sought to examine the efficacy of augmentation of antipsychotic treatment of schizophrenia patients with pregnenolone. It is hypothesized that the combined effect of antipsychotic agents and pregnenolone would be beneficial in the treatment of negative,depressive, and cognitive symptoms.

Timeline

Start
2005-01
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregnenolone Other / unclassified 30 mg
Subject Pregnenolone Other / unclassified 200 mg

Indications